[CAS NO. 216503-57-0] Alemtuzumab

Name: Alemtuzumab
Brand: Arctom Scientific
SKU: HY-P9948

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [216503-57-0]

Distributor

Catalog

HY-P9948

Brand

MCE

CAS

216503-57-0

DESCRIPTION [216503-57-0]

Overview

MDL	-
Molecular Weight	-
Molecular Formula	-
SMILES	[Alemtuzumab]

For research use only. We do not sell to patients.

Summary

Alemtuzumab (Campath-IH) is a humanized monoclonal antibody against CD52 , a glycoprotein expressed on the surface of most lymphoid, and to a lesser extent, myeloid cell types. Alemtuzumab selectively targets the CD52 antigen to induce profound lymphocyte depletion, followed by recovery of T and B cells with regulatory phenotypes ^[1] ^[2] .

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT00038844	M.D. Anderson Cancer Center	Lymphoma\|Leukemia	June 2001	Not Applicable
NCT02867800	Monica Bhatia\|Columbia University	Sickle Cell Disease\|Graft Versus Host Disease	July 2016	Phase 1
NCT03421756	Kathleen Dorritie\|University of Pittsburgh	Sickle Cell Disease	March 29, 2018	Early Phase 1
NCT02653196	Montefiore Medical Center\|Children´s Hospital Los Angeles\|Nationwide Children´s Hospital	Neuroepithelial Tumor\|Solid Tumor\|Allogeneic Hematopoietic Stem Cell Transplantation	September 2015	Early Phase 1
NCT00195624	National Heart, Lung, and Blood Institute (NHLBI)\|National Institutes of Health Clinical Center (CC)	Severe Aplastic Anemia, Refractory\|Severe Aplastic Anemia, Relapse	September 15, 2005	Phase 2
NCT01806337	University of Göttingen	Peripheral T-Cell Lymphoma	July 2003	Phase 2
NCT00618540	Masonic Cancer Center, University of Minnesota	Histiocytosis, Langerhans-cell	January 2007	Phase 2
NCT01256398	National Cancer Institute (NCI)	Acute Lymphoblastic Leukemia\|Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1	December 14, 2010	Phase 2
NCT00410657	Fred Hutchinson Cancer Center\|National Cancer Institute (NCI)	Breast Cancer\|Chronic Myeloproliferative Disorders\|Gestational Trophoblastic Tumor\|Graft Versus Host Disease\|Leukemia\|Lymphoma\|Multiple Myeloma and Plasma Cell Neoplasm\|Myelodysplastic Syndromes\|Myelodysplastic+Myeloproliferative Diseases\|Neuroblastoma\|Ovarian Cancer\|Testicular Germ Cell Tumor	July 2006	Phase 2
NCT01408342	Hospital Universitario Dr. Jose E. Gonzalez	Aplastic Anemia	July 2011	Not Applicable
NCT00773149	Assistance Publique - Hôpitaux de Paris	Acute Lymphocytic Leukemia	October 2006	Phase 1\|Phase 2
NCT02105766	National Heart, Lung, and Blood Institute (NHLBI)\|National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	Sickle Cell Disease\|Thalassemia\|Stem Cell Transplantation\|Graft vs Host Disease	April 21, 2014	Phase 2
NCT01625351	St. Jude Children´s Research Hospital\|CURE Childhood Cancer, Inc.	Ewing Sarcoma\|Gastrointestinal Tumor\|Germ Cell Tumor\|Hepatic Tumor\|Lymphoma\|Wilms Tumor\|Rhabdoid Tumor\|Clear Cell Carcinoma\|Renal Cell Carcinoma\|Melanoma\|Neuroblastoma\|Rhabdomyosarcoma\|Non-rhabdomyosarcoma	August 20, 2012	Phase 1
NCT02205489	Genzyme, a Sanofi Company\|Sanofi	Relapsing-remitting Multiple Sclerosis	October 2014	Phase 4
NCT04633967	Maritime Neurology	Frequency of Infusion Reactions in Novel Versus Standard Protocol in Multiple Sclerosis	May 15, 2016
NCT00801931	Columbia University	Leukemia\|Lymphoma\|Neuroblastoma\|Immunodeficiencies\|Anemia	September 6, 2007	Phase 1\|Phase 2
NCT00074282	Eastern Cooperative Oncology Group\|National Cancer Institute (NCI)	Leukemia	December 16, 2004	Phase 2
NCT03587272	Allistair Abraham, MD\|Alberta Children´s Hospital\|The Hospital for Sick Children\|Levine Children´s Hospital\|Ann & Robert H Lurie Children´s Hospital of Chicago\|Children´s National Research Institute	Sickle Cell Disease	April 17, 2018	Phase 2
NCT02255656	Genzyme, a Sanofi Company\|Sanofi	Relapsing Remitting Multiple Sclerosis	January 7, 2015	Phase 4
NCT00669318	Mayo Clinic\|National Cancer Institute (NCI)	Leukemia\|Lymphoma	July 2008	Phase 2
NCT01982175	Shanghai Zhangjiang Biotechnology Limited Company	B-cell Chronic Lymphocytic Leukemia	July 2011	Phase 2
NCT00152100	St. Jude Children´s Research Hospital	Severe Combined Immunodeficiency	February 2004	Phase 1
NCT00634881	German CLL Study Group	Chronic Lymphocytic Leukemia	November 2003	Phase 1\|Phase 2
NCT02766465	Medical College of Wisconsin\|National Heart, Lung, and Blood Institute (NHLBI)\|Blood and Marrow Transplant Clinical Trials Network\|Dana-Farber Cancer Institute\|National Marrow Donor Program\|Emory University	Sickle Cell Disease	November 2016	Phase 2
NCT00525876	M.D. Anderson Cancer Center	Lymphoma	January 2005	Not Applicable
NCT00472433	Phramongkutklao College of Medicine and Hospital\|Bayer	Autoimmune Cytopenias	March 2007	Phase 2
NCT00057967	Northwestern University\|Millennium Pharmaceuticals, Inc.\|Genzyme, a Sanofi Company	Lymphoma	July 2000	Phase 2
NCT00230282	Steven E. Coutre\|Bayer\|Stanford University	Leukemia\|B-cell Leukemia\|Chronic Leukemia\|Chronic Lymphocytic Leukemia (CLL)	July 2004	Phase 2
NCT01659606	Boston Children´s Hospital\|Dana-Farber Cancer Institute\|Children´s Hospital Medical Center, Cincinnati\|Children´s Hospital Los Angeles\|Fred Hutchinson Cancer Research Center+University of Washington Cancer Consortium\|Baylor College of Medicine\|Children´s Hospital of Philadelphia\|University of Wisconsin, Madison\|Karolinska University Hospital\|Hackensack Meridian Health\|Duke University\|Oslo University Hospital\|Children´s Mercy Hospital Kansas City\|Mayo Clinic\|University of Chicago\|Massachusetts General Hospital	Dyskeratosis Congenita\|Hoyeraal Hreidarsson Syndrome\|Revesz Syndrome\|Aplastic Anemia	July 2012	Phase 2
NCT05501756	Children´s Hospital Medical Center, Cincinnati	Allogeneic Hematopoietic Cell Transplantation	November 2022	Phase 2
NCT02061800	Diane George\|Columbia University	Chronic Myeloid Leukemia (CML)\|Acute Myelogenous Leukemia (AML)\|Myelodysplastic Syndrome (MDS)\|Juvenile Myelomonocytic Leukemia (JMML)\|Acute Lymphoblastic Leukemia (ALL)\|Lymphoma (Hodgkin´s and Non-Hodgkin´s)	June 3, 2013	Phase 1\|Phase 2
NCT01729494	University of Cincinnati	Renal Transplantation	September 2012	Phase 4
NCT00344825	Genzyme, a Sanofi Company\|Sanofi	Leukemia, B-Cell, Chronic	January 2004
NCT00061945	National Cancer Institute (NCI)	Acute Undifferentiated Leukemia\|B-cell Adult Acute Lymphoblastic Leukemia\|B-cell Childhood Acute Lymphoblastic Leukemia\|L1 Adult Acute Lymphoblastic Leukemia\|L1 Childhood Acute Lymphoblastic Leukemia\|L2 Adult Acute Lymphoblastic Leukemia\|L2 Childhood Acute Lymphoblastic Leukemia\|Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia\|Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia\|Philadelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia\|T-cell Adult Acute Lymphoblastic Leukemia\|T-cell Childhood Acute Lymphoblastic Leukemia\|Untreated Adult Acute Lymphoblastic Leukemia\|Untreated Childhood Acute Lymphoblastic Leukemia	June 2003	Phase 1\|Phase 2
NCT00061568	National Heart, Lung, and Blood Institute (NHLBI)\|National Institutes of Health Clinical Center (CC)	Congenital Hemolytic Anemia\|Sickle Cell Disease	July 16, 2004	Phase 1\|Phase 2
NCT02059239	Weill Medical College of Cornell University	Hodgkin´s Lymphoma\|Non-Hodgkin´s Lymphoma	June 4, 2014	Phase 1\|Phase 2
NCT00061048	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	Acute T-Cell Leukemia-Lymphoma	May 2003	Phase 2
NCT00530348	Genzyme, a Sanofi Company\|Bayer\|Sanofi	Multiple Sclerosis, Relapsing-Remitting	August 2007	Phase 3
NCT00935792	Mayo Clinic	Lymphocytic Leukemia	July 2009	Phase 1\|Phase 2
NCT00006390	Eastern Cooperative Oncology Group\|National Cancer Institute (NCI)	Leukemia	February 2001	Phase 2
NCT01624714	Samuel Forrester Hunter, MD, PhD\|Advanced Neurosciences Institute	Multiple Sclerosis	September 2012	Phase 1
NCT03132584	Dana-Farber Cancer Institute\|Genzyme, a Sanofi Company\|Sanofi	Non Hodgkin Lymphoma\|High-grade B-cell Lymphoma\|Diffuse Large B Cell Lymphoma	July 30, 2017	Phase 1
NCT03302754	Children´s Hospital Medical Center, Cincinnati	Allogeneic Hematopoietic Cell Transplantation	October 5, 2017	Not Applicable
NCT00113269	Astellas Pharma Inc	Kidney Transplantation	May 2005	Phase 4
NCT02583594	Genzyme, a Sanofi Company\|Sanofi	Progressive Multiple Sclerosis	December 6, 2015	Phase 1
NCT00316810	Dr. Claudia Bösmüller\|Astellas Pharma GmbH\|Medical University Innsbruck	Pancreas-Kidney Transplantation	April 2006	Phase 3
NCT01395316	University of Chicago\|Genzyme, a Sanofi Company	Multiple Sclerosis	June 2011	Phase 4
NCT00109993	Case Comprehensive Cancer Center\|National Cancer Institute (NCI)	Breast Cancer\|Chronic Myeloproliferative Disorders\|Gestational Trophoblastic Tumor\|Graft Versus Host Disease\|Leukemia\|Lymphoma\|Multiple Myeloma and Plasma Cell Neoplasm\|Myelodysplastic Syndromes\|Myelodysplastic+Myeloproliferative Diseases\|Neuroblastoma\|Ovarian Cancer\|Testicular Germ Cell Tumor	January 2005	Phase 2
NCT00040417	Baylor College of Medicine\|The Methodist Hospital Research Institute	Sickle Cell Anemia\|Hemoglobinopathy\|Thalassemia	August 2000	Phase 2
NCT05463133	National Institute of Allergy and Infectious Diseases (NIAID)\|National Institutes of Health Clinical Center (CC)	Chronic Granulomatous Disease	July 8, 2022	Phase 1\|Phase 2
NCT01679041	Seah Lim M.D.\|Texas Oncology Cancer Center	Multiple Sclerosis	November 2012	Phase 2
NCT00217594	National Heart, Lung, and Blood Institute (NHLBI)\|National Institutes of Health Clinical Center (CC)	Myelodysplastic Syndromes	July 21, 2005	Phase 2
NCT03806387	University of Aarhus\|Genzyme, a Sanofi Company	Multiple Sclerosis	March 1, 2017
NCT00147381	Dr. Claudia Bösmüller\|Astellas Pharma GmbH\|Medical University Innsbruck	Kidney Transplantation	January 2004	Phase 3
NCT00383448	Masonic Cancer Center, University of Minnesota	Adrenoleukodystrophy\|Metachromatic Leukodystrophy\|Globoid Cell Leukodystrophy\|Tay Sachs Disease\|Sandhoffs Disease\|Wolman Disease\|I-Cell Disease\|Sanfilippo Syndrome\|GM1 Gangliosidosis	September 2006	Phase 2
NCT01499888	University of Illinois at Chicago	Sickle Cell Disease	November 11, 2011	Phase 1\|Phase 2
NCT03653338	Paul Szabolcs\|University of Pittsburgh	Sickle Cell Anemia\|Beta-thalassemia Major\|Diamond-blackfan Anemia	August 2, 2018	Phase 1\|Phase 2
NCT02472054	Assistance Publique - Hôpitaux de Paris	Hemophagocytic Lymphohistiocytosis (HLH)	June 29, 2015	Phase 1\|Phase 2
NCT00562328	Mayo Clinic\|National Cancer Institute (NCI)	Leukemia	January 2008	Phase 2
NCT02385110	M.D. Anderson Cancer Center	Leukemia	September 23, 2015	Phase 2
NCT00646854	Aarhus University Hospital\|GCP-unit at Aarhus University Hospital, Aarhus, Denmark\|University of Aarhus	Lymphoma, T-Cell, Peripheral	June 2008	Phase 3
NCT01877837	Hackensack Meridian Health	Sickle Cell Disease	June 2011	Phase 3
NCT05357482	National Heart, Lung, and Blood Institute (NHLBI)\|National Institutes of Health Clinical Center (CC)	Sickle Cell Anemia\|Beta Thalassemia	May 12, 2022	Phase 1\|Phase 2
NCT02689453	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	T-Cell Lymphoma Relapsed\|Adult T-Cell Leukemia (ATL)\|Peripheral T-Cell Lymphoma (PTCL)\|Cutaneous T Cell Lymphoma (CTCL)\|T-Cell Prolymphocytic Leukemia	January 19, 2017	Phase 1
NCT03821610	University of Birmingham	Acute Lymphoblastic Leukemia	November 22, 2018	Phase 2
NCT01191749	M.D. Anderson Cancer Center	Leukemia	August 2010	Phase 2
NCT00626626	Milton S. Hershey Medical Center	Leukemia\|Myelodysplastic Syndrome\|Chronic Myelogenous Leukemia\|Lymphoma\|Hodgkin´s Lymphoma\|Multiple Myeloma	May 2007	Phase 1\|Phase 2
NCT00363090	Toronto Sunnybrook Regional Cancer Centre\|National Cancer Institute (NCI)	Lymphoma	September 2006	Phase 1\|Phase 2
NCT00525603	M.D. Anderson Cancer Center\|Bayer	Leukemia\|Chronic Lymphocytic Leukemia	June 2005	Phase 2
NCT01361711	Northwestern University\|GlaxoSmithKline\|National Comprehensive Cancer Network	Stage I Chronic Lymphocytic Leukemia\|Stage II Chronic Lymphocytic Leukemia\|Stage III Chronic Lymphocytic Leukemia\|Stage IV Chronic Lymphocytic Leukemia	June 2011	Phase 2
NCT00162851	Karolinska University Hospital\|Schering Nordiska AB	B-CLL	April 2003	Phase 2
NCT00947388	Case Comprehensive Cancer Center\|Cephalon	Recurrent Small Lymphocytic Lymphoma\|Refractory Chronic Lymphocytic Leukemia\|Stage III Chronic Lymphocytic Leukemia\|Stage III Small Lymphocytic Lymphoma\|Stage IV Chronic Lymphocytic Leukemia\|Stage IV Small Lymphocytic Lymphoma	November 2008	Phase 1
NCT02629120	National Institute of Allergy and Infectious Diseases (NIAID)\|National Institutes of Health Clinical Center (CC)	Chronic Granulomatous Disease Transplant	December 17, 2015	Phase 1\|Phase 2
NCT02013375	Damiano Rondelli, MD\|University of Illinois at Chicago	Sickle Cell Disease	April 10, 2014	Phase 2
NCT01518153	M.D. Anderson Cancer Center	Leukemia\|Lymphoma\|Myeloma\|Myeloproliferative Diseases	February 2012	Phase 2
NCT00858117	Northwestern University\|Bayer	Leukemia	September 26, 2005	Phase 2
NCT00930605	King Chulalongkorn Memorial Hospital\|Bayer	Peripheral T-cell Lymphoma	January 2005	Phase 2
NCT02435901	Northwell Health	Sickle Cell Disease\|Beta Thalassemia-Major	December 2008	Phase 1\|Phase 2
NCT00328198	Genzyme, a Sanofi Company\|Bayer Healthcare Pharmaceuticals, Inc.+Bayer Schering Pharma\|Sanofi	B-Cell Chronic Lymphocytic Leukemia (B-CLL)	May 2006	Phase 2
NCT00520130	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	Myelodysplastic Syndrome\|Hodgkin´s Lymphoma\|Non-Hodgkin´s Disease\|Acute Leukemia\|Multiple Myeloma	October 30, 2007	Phase 1\|Phase 2
NCT00337519	Charite University, Berlin, Germany\|University Hospital Carl Gustav Carus\|Deutsche Klinik fuer Diagnostik	Chronic Lymphocytic Leukemia	January 2003	Phase 2
NCT00986557	University Hospital Birmingham\|National Cancer Institute (NCI)	Graft Versus Host Disease\|Nonneoplastic Condition	September 2009	Phase 2
NCT01042509	Hospital Universitario Dr. Jose E. Gonzalez	Graft vs Host Disease	October 2009	Not Applicable
NCT00301834	University of California, San Francisco\|National Cancer Institute (NCI)	Congenital Amegakaryocytic Thrombocytopenia\|Diamond-blackfan Anemia\|Leukemia\|Myelodysplastic Syndromes\|Severe Congenital Neutropenia	January 2005	Phase 2
NCT01405807	Cambridge University Hospitals NHS Foundation Trust	Vasculitis\|Microscopic Polyangiitis\|Granulomatosis With Polyangiitis\|Wegener´s	February 2011	Phase 4
NCT00818961	Northside Hospital, Inc.\|Blood and Marrow Transplant Group of Georgia	Leukemia\|Lymphoma\|Myelodysplastic Syndromes\|Myelodysplastic+Myeloproliferative Diseases	May 2005	Phase 2
NCT01269385	Mayo Clinic\|National Cancer Institute (NCI)	B-cell Chronic Lymphocytic Leukemia\|Refractory Chronic Lymphocytic Leukemia\|Stage 0 Chronic Lymphocytic Leukemia\|Stage I Chronic Lymphocytic Leukemia\|Stage II Chronic Lymphocytic Leukemia	January 2011	Phase 1\|Phase 2
NCT00923182	Genzyme, a Sanofi Company\|Sanofi	Leukemia, Lymphocytic, Chronic, B-Cell	February 2010	Phase 1
NCT00175253	University of Alberta\|Juvenile Diabetes Research Foundation	Type 1 Diabetes	November 2005	Phase 2
NCT04154735	Northwestern University	Crohn´s Disease	November 2019	Phase 2
NCT00089349	National Cancer Institute (NCI)	Recurrent Childhood Acute Lymphoblastic Leukemia	July 2004	Phase 2
NCT00725231	University of Göttingen\|German High-Grade Non-Hodgkin´s Lymphoma Study Group\|Nordic Lymphoma Group	Peripheral T Cell Lymphoma, Unspecified\|Angioimmunoblastic Lymphadenopathy\|Extranodal NK+T-cell Lymphoma	February 2008	Phase 3
NCT03989466	M.D. Anderson Cancer Center	Recurrent T-Cell Prolymphocytic Leukemia\|T-Cell Prolymphocytic Leukemia	January 15, 2020	Phase 1
NCT00098670	National Cancer Institute (NCI)	B-cell Chronic Lymphocytic Leukemia\|Stage I Chronic Lymphocytic Leukemia\|Stage II Chronic Lymphocytic Leukemia\|Stage III Chronic Lymphocytic Leukemia\|Stage IV Chronic Lymphocytic Leukemia	October 2004	Phase 2
NCT03477500	Haukeland University Hospital	Multiple Sclerosis	March 21, 2018	Phase 3
NCT01652092	Masonic Cancer Center, University of Minnesota	SCID\|Omenn´s Syndrome\|Reticular Dysgenesis\|Wiskott-Aldrich Syndrome\|Bare Lymphocyte Syndrome\|Common Variable Immunodeficiency\|Chronic Granulomatous Disease\|CD40 Ligand Deficiency\|Hyper IgM Syndrome\|X-linked Lymphoproliferative Disease\|Hemophagocytic Lymphohistiocytosis\|Griscelli Syndrome\|Chediak-Higashi Syndrome\|Langerhan´s Cell Histiocytosis	September 4, 2012	Not Applicable
NCT03182426	University of Alberta\|Alberta Innovates Health Solutions	Diabetes Mellitus, Type 1	August 15, 2017	Phase 1\|Phase 2
NCT00161590	Weill Medical College of Cornell University\|Bayer	T-Cell Lymphoma\|Lymphoma, Non-Hodgkin´s	July 2004	Phase 1
NCT00104975	Yale University\|National Cancer Institute (NCI)	Chronic Myeloproliferative Disorders\|Leukemia\|Lymphoma\|Myelodysplastic Syndromes\|Myelodysplastic+Myeloproliferative Neoplasms	February 2005	Phase 1
NCT00143065	Ohio State University Comprehensive Cancer Center	Lymphoma, Small Lymphocytic\|Lymphocytic Leukemia, Chronic	August 2005	Phase 2
NCT00453427	Ontario Clinical Oncology Group (OCOG)\|Sunnybrook Health Sciences Centre\|Genzyme, a Sanofi Company	Peripheral T-cell Lymphomas	September 2006	Phase 1\|Phase 2
NCT00206726	Genzyme, a Sanofi Company\|Sanofi	Leukemia, Lymphocytic, Chronic, B-Cell	May 2005	Phase 2
NCT00548405	Genzyme, a Sanofi Company\|Bayer\|Sanofi	Multiple Sclerosis, Relapsing-Remitting	October 2007	Phase 3
NCT00566696	St. Jude Children´s Research Hospital	Leukemia, Acute Lymphocytic (ALL)\|Leukemia, Myeloid, Acute(AML)\|Leukemia, Myeloid, Chronic(CML)\|Juvenile Myelomonocytic Leukemia (JMML)\|Hemoglobinuria, Paroxysmal Nocturnal (PNH)\|Hodgkin Lymphoma\|Lymphoma, Non-Hodgkin (NHL)\|Myelodysplastic Syndrome (MDS)	December 14, 2007	Phase 2
NCT00800943	Chronic Lymphocytic Leukemia Research Consortium\|Bayer	B-Cell Chronic Lymphocytic Leukemia	December 2003	Phase 2
NCT04971005	Universitätsklinikum Hamburg-Eppendorf\|Neovii Biotech\|Clinical Trial Center North (CTC North GmbH & Co. KG)	Relapsing-Remitting Multiple Sclerosis	August 27, 2021	Phase 2
NCT00078559	University of Wisconsin, Madison\|Immune Tolerance Network (ITN)	Kidney Transplantation\|Kidney Disease	November 2003	Phase 1\|Phase 2
NCT00046683	Genzyme, a Sanofi Company\|Sanofi	B Cell Chronic Lymphocytic Leukemia	July 2001	Phase 3
NCT00021151	Case Comprehensive Cancer Center\|National Cancer Institute (NCI)\|Genzyme, a Sanofi Company	Leukemia	January 2000	Not Applicable
NCT01213329	Northwestern University\|American Society of Transplant Surgeons	Kidney Transplant	February 2006	Phase 4
NCT03910452	National Institute of Allergy and Infectious Diseases (NIAID)\|National Institutes of Health Clinical Center (CC)	Chronic Granulomatous Disease	October 28, 2019	Early Phase 1
NCT00408447	Columbia University	Sickle Cell Disease\|Beta Thalassemia	September 2004	Phase 2
NCT03214354	University of Calgary	Sickle Cell Disease\|Stem Cell Transplant Complications\|Red Blood Cell Disorder\|Pure Red Cell Aplasia	July 5, 2017	Phase 2
NCT00553098	Fred Hutchinson Cancer Center\|National Cancer Institute (NCI)\|National Heart, Lung, and Blood Institute (NHLBI)	Immunodeficiency Syndrome\|Non-Cancer Diagnosis	June 2006	Phase 2
NCT01186640	German CLL Study Group\|Genzyme, a Sanofi Company\|University of Cologne	T-cell-prolymphocytic Leukemia	June 2010	Phase 2
NCT01465334	Dana-Farber Cancer Institute\|National Comprehensive Cancer Network\|GlaxoSmithKline	CLL\|SLL	December 2011	Phase 2
NCT01962415	Paul Szabolcs\|University of Pittsburgh	Primary Immunodeficiency (PID)\|Congenital Bone Marrow Failure Syndromes\|Inherited Metabolic Disorders (IMD)\|Hereditary Anemias\|Inflammatory Conditions	February 4, 2014	Phase 2
NCT00330252	Dana-Farber Cancer Institute\|Genzyme, a Sanofi Company	Chronic Lymphocytic Leukemia	May 2006	Phase 1
NCT03368664	Genzyme, a Sanofi Company\|Sanofi	Multiple Sclerosis	October 24, 2017	Phase 3
NCT02419378	University Hospital Muenster\|Genzyme, a Sanofi Company	Multiple Sclerosis, Relapsing-Remitting	June 2015	Phase 4
NCT00441025	Mahidol University\|Bayer	Peripheral T-Cell Lymphoma	September 2006	Phase 2
NCT00331162	Wake Forest University Health Sciences	Graft Rejection	February 2005	Phase 4
NCT00214214	University of Wisconsin, Madison	New Onset Type 1 Diabetes Mellitus	October 2005	Phase 1
NCT00040846	Fred Hutchinson Cancer Center\|National Heart, Lung, and Blood Institute (NHLBI)\|National Cancer Institute (NCI)	Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Del(5q)\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|Adult Nasal Type Extranodal NK+T-cell Lymphoma\|Anaplastic Large Cell Lymphoma\|Angioimmunoblastic T-cell Lymphoma\|Childhood Burkitt Lymphoma\|Childhood Chronic Myelogenous Leukemia\|Childhood Diffuse Large Cell Lymphoma\|Childhood Immunoblastic Large Cell Lymphoma\|Childhood Nasal Type Extranodal NK+T-cell Lymphoma\|Chronic Phase Chronic Myelogenous Leukemia\|Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma\|Contiguous Stage II Grade 1 Follicular Lymphoma\|Contiguous Stage II Grade 2 Follicular Lymphoma\|Contiguous Stage II Marginal Zone Lymphoma\|Contiguous Stage II Small Lymphocytic Lymphoma\|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue\|Hepatosplenic T-cell Lymphoma\|Myelodysplastic+Myeloproliferative Neoplasm, Unclassifiable\|Nodal Marginal Zone B-cell Lymphoma\|Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma\|Noncontiguous Stage II Grade 1 Follicular Lymphoma\|Noncontiguous Stage II Grade 2 Follicular Lymphoma\|Noncontiguous Stage II Marginal Zone Lymphoma\|Noncontiguous Stage II Small Lymphocytic Lymphoma\|Peripheral T-cell Lymphoma\|Previously Treated Myelodysplastic Syndromes\|Progressive Hairy Cell Leukemia, Initial Treatment\|Recurrent Adult Acute Myeloid Leukemia\|Recurrent Adult Burkitt Lymphoma\|Recurrent Adult Diffuse Large Cell Lymphoma\|Recurrent Adult Diffuse Mixed Cell Lymphoma\|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma\|Recurrent Adult Grade III Lymphomatoid Granulomatosis\|Recurrent Adult Hodgkin Lymphoma\|Recurrent Adult Immunoblastic Large Cell Lymphoma\|Recurrent Adult Lymphoblastic Lymphoma\|Recurrent Adult T-cell Leukemia+Lymphoma\|Recurrent Childhood Acute Lymphoblastic Leukemia\|Recurrent Childhood Acute Myeloid Leukemia\|Recurrent Childhood Anaplastic Large Cell Lymphoma\|Recurrent Childhood Large Cell Lymphoma\|Recurrent Childhood Lymphoblastic Lymphoma\|Recurrent Childhood Small Noncleaved Cell Lymphoma\|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Grade 3 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Recurrent Mycosis Fungoides+Sezary Syndrome\|Recurrent Small Lymphocytic Lymphoma\|Recurrent+Refractory Childhood Hodgkin Lymphoma\|Refractory Chronic Lymphocytic Leukemia\|Refractory Hairy Cell Leukemia\|Refractory Multiple Myeloma\|Relapsing Chronic Myelogenous Leukemia\|Splenic Marginal Zone Lymphoma\|Stage I Adult Diffuse Small Cleaved Cell Lymphoma\|Stage I Childhood Anaplastic Large Cell Lymphoma\|Stage I Childhood Large Cell Lymphoma\|Stage I Cutaneous T-cell Non-Hodgkin Lymphoma\|Stage I Grade 1 Follicular Lymphoma\|Stage I Grade 2 Follicular Lymphoma\|Stage I Mantle Cell Lymphoma\|Stage I Marginal Zone Lymphoma\|Stage I Mycosis Fungoides+Sezary Syndrome\|Stage I Small Lymphocytic Lymphoma\|Stage II Childhood Anaplastic Large Cell Lymphoma\|Stage II Childhood Large Cell Lymphoma\|Stage II Cutaneous T-cell Non-Hodgkin Lymphoma\|Stage II Mycosis Fungoides+Sezary Syndrome\|Stage III Adult Diffuse Large Cell Lymphoma\|Stage III Adult Diffuse Small Cleaved Cell Lymphoma\|Stage III Childhood Anaplastic Large Cell Lymphoma\|Stage III Childhood Large Cell Lymphoma\|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma\|Stage III Grade 1 Follicular Lymphoma\|Stage III Grade 2 Follicular Lymphoma\|Stage III Mantle Cell Lymphoma\|Stage III Marginal Zone Lymphoma\|Stage III Mycosis Fungoides+Sezary Syndrome\|Stage III Small Lymphocytic Lymphoma\|Stage IV Adult Diffuse Large Cell Lymphoma\|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma\|Stage IV Childhood Anaplastic Large Cell Lymphoma\|Stage IV Childhood Large Cell Lymphoma\|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma\|Stage IV Grade 1 Follicular Lymphoma\|Stage IV Grade 2 Follicular Lymphoma\|Stage IV Mantle Cell Lymphoma\|Stage IV Marginal Zone Lymphoma\|Stage IV Mycosis Fungoides+Sezary Syndrome\|Stage IV Small Lymphocytic Lymphoma\|T-cell Large Granular Lymphocyte Leukemia\|Waldenström Macroglobulinemia	November 2001	Phase 2
NCT00153985	Dana-Farber Cancer Institute\|Beth Israel Deaconess Medical Center\|Massachusetts General Hospital\|Brigham and Women´s Hospital\|Emory University\|Feist-Weiller Cancer Center at Louisiana State University Health Sciences\|Ohio State University	Hemoglobinopathies\|Sickle Cell Disease\|Thalassemia	March 2004	Phase 2
NCT00692939	Paul Szabolcs\|University of Pittsburgh	Crohn´s Disease	June 26, 2012	Phase 1\|Phase 2
NCT00781781	CABYC\|Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea	Graft Versus Host Disease	July 2008	Phase 2
NCT00081068	Jonsson Comprehensive Cancer Center\|National Cancer Institute (NCI)	Lymphoma	January 2004	Phase 2
NCT00871546	Merck Sharp & Dohme LLC	Lymphoma, Mantle-Cell\|Leukemia, Lymphocytic, Chronic, B-Cell	March 2009	Phase 2
NCT01875237	M.D. Anderson Cancer Center\|Bellicum Pharmaceuticals	Leukemia\|Myeloma\|Myeloproliferative Diseases	December 27, 2013	Phase 1\|Phase 2
NCT00278213	German CLL Study Group	Prolymphocytic Leukemia	September 2002	Phase 2
NCT00775632	University Health Network, Toronto\|Bayer	Graft Versus Host Disease\|Bone Marrow Transplantation	October 2008	Phase 2
NCT00274976	German CLL Study Group\|National Cancer Institute (NCI)	Leukemia	September 2002	Phase 2
NCT00262925	National Cancer Institute (NCI)	Recurrent Adult Acute Lymphoblastic Leukemia	June 2006	Phase 2
NCT00637390	University of Michigan Rogel Cancer Center	Ovarian Cancer\|Fallopian Tube Cancer\|Peritoneal Cancer	March 2008	Phase 1
NCT00199030	Johann Wolfgang Goethe University Hospital	Adult Acute Lymphocytic Leukemia T-Cell\|Lymphoma, Lymphoblastic	February 2004	Phase 2
NCT04339777	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	Lymphoproliferative Disorders\|Autoimmune Lymphoproliferative\|Immune System Diseases\|Common Variable Immunodeficiency\|Primary T-cell Immunodeficiency Disorders	September 22, 2020	Phase 2
NCT01436305	National Institute of Allergy and Infectious Diseases (NIAID)\|Clinical Trials in Organ Transplantation	Kidney Transplantation\|Renal Transplantation	September 2011	Phase 2
NCT00183248	University of Miami\|Immune Tolerance Network (ITN)	Kidney Transplantation\|Kidney Disease\|Kidney Failure	September 2004	Phase 1\|Phase 2
NCT00085449	Alliance for Clinical Trials in Oncology\|National Cancer Institute (NCI)	Leukemia\|Lymphoma\|Multiple Myeloma and Plasma Cell Neoplasm\|Myelodysplastic Syndromes\|Myelodysplastic+Myeloproliferative Neoplasms	May 2006	Phase 1\|Phase 2
NCT00079768	National Institute of Neurological Disorders and Stroke (NINDS)\|National Institutes of Health Clinical Center (CC)	Myositis, Inclusion Body	March 2004	Phase 2
NCT00565981	Arbeitsgemeinschaft medikamentoese Tumortherapie\|Schering-Plough	B-cell Chronic Lymphocytic Leukemia	March 2004	Phase 2
NCT00113048	Genzyme, a Sanofi Company\|Sanofi	Hematologic Malignancies	December 2003	Phase 1
NCT00983528	University of California, San Diego\|Genzyme, a Sanofi Company	Acute Lymphoblastic Leukemia	September 2009	Phase 1\|Phase 2
NCT00562068	Cancer Research UK\|National Cancer Institute (NCI)	Lymphoma\|Small Intestine Cancer	May 2007	Phase 1
NCT03135249	University of Texas Southwestern Medical Center\|Genzyme, a Sanofi Company	Multiple Sclerosis (MS)	May 1, 2018	Phase 4
NCT00895739	Federico II University\|National Cancer Institute (NCI)	Nonmalignant Neoplasm	June 2006	Phase 2
NCT00881556	Columbia University	Epidermolysis Bullosa	August 20, 2009	Early Phase 1
NCT00073879	Baylor College of Medicine	Kidney Cancer	April 2003	Not Applicable
NCT00907036	Cancer Research UK\|National Cancer Institute (NCI)	Lymphoma	July 2009	Phase 2
NCT01013961	ECOG-ACRIN Cancer Research Group\|National Cancer Institute (NCI)\|Eastern Cooperative Oncology Group	Chronic Lymphocytic Leukemia	October 2010	Phase 2
NCT00930553	Genzyme, a Sanofi Company\|Bayer\|Sanofi	Multiple Sclerosis, Relapsing-Remitting	August 2009	Phase 3
NCT00565773	Allan D Kirk, MD, PhD\|Bristol-Myers Squibb\|Duke University\|Emory University	Organ Transplantation	December 2007	Phase 2
NCT03630211	Paul Szabolcs\|University of Pittsburgh	Systemic Sclerosis\|Diffuse Sclerosis Systemic\|Interstitial Lung Disease\|Pulmonary Hypertension	July 31, 2018	Phase 2
NCT00175266	University of Alberta\|Juvenile Diabetes Research Foundation	Type 1 Diabetes		Phase 2
NCT00069238	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	Lymphoma, T-Cell\|Lymphoma, Extranodal NK-T-Cell	September 19, 2003	Phase 2
NCT01596699	University of California, San Francisco	Myeloid Malignancy\|Bone Marrow Failure Syndrome\|Transfusion-dependent Red Blood Cell (RBC) Defect\|Congenital Immunodeficiency\|Metabolic Disease\|Severe Immune Dysregulation	May 24, 2012	Phase 2
NCT00336206	Tawam Hospital	B-Cell Chronic Lymphocytic Leukemia	July 2006	Not Applicable
NCT00260689	National Heart, Lung, and Blood Institute (NHLBI)\|National Institutes of Health Clinical Center (CC)	Immunosuppresion\|Thrombocytopenia\|Pancytopenia\|Neutropenia	November 28, 2005	Phase 2
NCT00458523	Leeds Cancer Centre at St. James´s University Hospital\|National Cancer Institute (NCI)	Leukemia	December 2006	Phase 2
NCT00050778	Genzyme, a Sanofi Company\|Bayer\|Sanofi	Multiple Sclerosis, Relapsing-Remitting	December 2002	Phase 2
NCT00345345	National Heart, Lung, and Blood Institute (NHLBI)\|National Institutes of Health Clinical Center (CC)	T-LGL Lymphoproliferative Disorders	October 17, 2006	Phase 2
NCT01082939	M.D. Anderson Cancer Center\|Bayer	Chronic Lymphocytic Leukemia	December 2002	Phase 2
NCT00977691	National Heart, Lung, and Blood Institute (NHLBI)\|National Institutes of Health Clinical Center (CC)	Sickle Cell Anemia	December 14, 2009	Phase 1\|Phase 2
NCT00720447	Cancer Research UK\|National Cancer Institute (NCI)	Lymphoma	November 2008	Phase 2
NCT03500731	Paul Szabolcs\|University of Pittsburgh	Idiopathic Pulmonary Fibrosis\|Emphysema or COPD	April 19, 2018	Phase 1\|Phase 2
NCT01208337	University of Pittsburgh	Evidence of Liver Transplantation\|Rejection\|ALEMTUZUMAB	April 2007	Phase 2
NCT00105235	National Institute of Allergy and Infectious Diseases (NIAID)\|Immune Tolerance Network (ITN)	Liver Disease\|Liver Transplantation	June 2005	Phase 2
NCT00292760	Royal Marsden NHS Foundation Trust	Chronic Lymphocytic Leukaemia		Phase 2
NCT02529839	Hadassah Medical Organization	Multiple Sclerosis	October 2015	Not Applicable
NCT00027560	Memorial Sloan Kettering Cancer Center\|National Cancer Institute (NCI)	Leukemia\|Lymphoma\|Multiple Myeloma and Plasma Cell Neoplasm\|Myelodysplastic Syndromes\|Myelodysplastic+Myeloproliferative Neoplasms	July 2001	Phase 2
NCT00166712	Northwestern University\|Roche Pharma AG	Kidney Transplant Failure and Rejection	April 2005	Phase 4
NCT01757574	Johns Hopkins University\|Genzyme, a Sanofi Company	Chronic Inflammatory Demyelinating Neuropathy	November 2012	Phase 4
NCT01172418	University of Miami	Transplant; Failure, Kidney	February 2006	Phase 4
NCT05384756	City of Hope Medical Center\|National Cancer Institute (NCI)	Sickle Cell Disease	July 13, 2022	Phase 1
NCT00077961	Genzyme, a Sanofi Company\|Sanofi	Non-Hodgkin´s Lymphoma	December 2003	Phase 1\|Phase 2
NCT04082260	University Hospital Muenster	Multiple Sclerosis	January 2017
NCT00323323	Ohio State University Comprehensive Cancer Center\|Bayer	Non-Hodgkin´s Lymphoma	March 2004	Phase 1
NCT00555048	Fred Hutchinson Cancer Center\|National Cancer Institute (NCI)	Graft Versus Host Disease\|Leukemia\|Myelodysplastic Syndromes\|Myelodysplastic+Myeloproliferative Diseases	September 2007	Phase 1\|Phase 2
NCT02497404	Weill Medical College of Cornell University	Leukemia, Erythroblastic, Acute\|Myelodysplastic Syndromes	February 13, 2015	Phase 2
NCT00240994	National Institute of Allergy and Infectious Diseases (NIAID)\|Cooperative Clinical Trials in Pediatric Transplantation	Kidney Failure, Chronic\|Kidney Transplantation\|Immunosuppression	January 2005	Phase 2
NCT00908180	Cancer Research UK\|National Cancer Institute (NCI)	Lymphoma	July 2009	Phase 2
NCT00086775	Bayer\|National Cancer Institute (NCI)	Leukemia	July 2003	Phase 2
NCT01333358	Central Texas Neurology Consultants\|Genzyme, a Sanofi Company	Multiple Sclerosis	May 2011	Phase 3
NCT04232085	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Primary Immune Deficiency Disorder\|Immune Deficiency Disease\|Bone Marrow Failure	February 12, 2020	Phase 2
NCT03774914	Genzyme, a Sanofi Company\|Sanofi	Multiple Sclerosis	September 1, 2015
NCT03250169	Queen Mary University of London	Multiple Sclerosis	August 1, 2017
NCT00578643	Baylor College of Medicine	Chronic Granulomatous Disease	March 2004	Phase 2
NCT00118352	Fred Hutchinson Cancer Center\|National Cancer Institute (NCI)	Acute Undifferentiated Leukemia\|Adult Acute Lymphoblastic Leukemia in Remission\|Adult Acute Myeloid Leukemia in Remission\|Adult Nasal Type Extranodal NK+T-cell Lymphoma\|Anaplastic Large Cell Lymphoma\|Angioimmunoblastic T-cell Lymphoma\|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative\|Childhood Acute Lymphoblastic Leukemia in Remission\|Childhood Acute Myeloid Leukemia in Remission\|Childhood Burkitt Lymphoma\|Childhood Chronic Myelogenous Leukemia\|Childhood Diffuse Large Cell Lymphoma\|Childhood Immunoblastic Large Cell Lymphoma\|Childhood Myelodysplastic Syndromes\|Childhood Nasal Type Extranodal NK+T-cell Lymphoma\|Chronic Myelomonocytic Leukemia\|Chronic Phase Chronic Myelogenous Leukemia\|Cutaneous B-cell Non-Hodgkin Lymphoma\|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue\|Hepatosplenic T-cell Lymphoma\|Intraocular Lymphoma\|Juvenile Myelomonocytic Leukemia\|Mast Cell Leukemia\|Myelodysplastic+Myeloproliferative Neoplasm, Unclassifiable\|Nodal Marginal Zone B-cell Lymphoma\|Noncutaneous Extranodal Lymphoma\|Peripheral T-cell Lymphoma\|Previously Treated Myelodysplastic Syndromes\|Recurrent Adult Acute Lymphoblastic Leukemia\|Recurrent Adult Acute Myeloid Leukemia\|Recurrent Adult Burkitt Lymphoma\|Recurrent Adult Diffuse Large Cell Lymphoma\|Recurrent Adult Diffuse Mixed Cell Lymphoma\|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma\|Recurrent Adult Grade III Lymphomatoid Granulomatosis\|Recurrent Adult Hodgkin Lymphoma\|Recurrent Adult Immunoblastic Large Cell Lymphoma\|Recurrent Adult Lymphoblastic Lymphoma\|Recurrent Adult T-cell Leukemia+Lymphoma\|Recurrent Childhood Acute Lymphoblastic Leukemia\|Recurrent Childhood Acute Myeloid Leukemia\|Recurrent Childhood Anaplastic Large Cell Lymphoma\|Recurrent Childhood Grade III Lymphomatoid Granulomatosis\|Recurrent Childhood Large Cell Lymphoma\|Recurrent Childhood Lymphoblastic Lymphoma\|Recurrent Childhood Small Noncleaved Cell Lymphoma\|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Grade 3 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Recurrent Mycosis Fungoides+Sezary Syndrome\|Recurrent Small Lymphocytic Lymphoma\|Recurrent+Refractory Childhood Hodgkin Lymphoma\|Refractory Chronic Lymphocytic Leukemia\|Refractory Hairy Cell Leukemia\|Refractory Multiple Myeloma\|Relapsing Chronic Myelogenous Leukemia\|Secondary Myelodysplastic Syndromes\|Small Intestine Lymphoma\|Splenic Marginal Zone Lymphoma\|Testicular Lymphoma\|Waldenström Macroglobulinemia	March 2005	Phase 2
NCT00129753	M.D. Anderson Cancer Center	Hodgkin´s Disease\|Lymphoma	June 22, 2005	Phase 2
NCT01392079	University of Ulm\|Technical University of Munich\|WiSP Wissenschaftlicher Service Pharma GmbH\|German CLL Study Group	Chronic Lymphocytic Leukemia	February 2008	Phase 2
NCT00454480	The University of New South Wales\|National Cancer Institute (NCI)	Leukemia\|Myelodysplastic Syndromes	August 2006	Phase 2\|Phase 3
NCT00495755	Dana-Farber Cancer Institute\|Genzyme, a Sanofi Company\|Bayer	Chronic Graft-vs.-Host Disease	July 2007	Phase 1
NCT00157274	Latin American Cooperative Onco-Haematology Group - Peru	Mycosis Fungoides\|Sezary Syndrome	July 2005	Phase 2
NCT01712945	Cambridge University Hospitals NHS Foundation Trust	Multiple Sclerosis	June 2012	Phase 1\|Phase 2
NCT00177138	University of Minnesota\|Bayer\|Gruessner, Rainer, MD	Diabetes Mellitus	July 2004	Phase 4
NCT02678143	Washington University School of Medicine	Sickle Cell Disease	April 26, 2016	Phase 1
NCT00951457	Arbeitsgemeinschaft medikamentoese Tumortherapie\|Mundipharma Pte Ltd.	Leukemia, Lymphocytic, Chronic, B-Cell	March 2009	Phase 1\|Phase 2
NCT00453193	M.D. Anderson Cancer Center\|Astex Pharmaceuticals, Inc.\|Bayer	Lymphoma\|Leukemia	September 2004	Phase 2
NCT00997386	University of Arizona	Hematologic Neoplasms\|Multiple Myeloma\|Anemia, Aplastic\|Hemoglobinuria, Paroxysmal\|Myelofibrosis	September 2009	Phase 2
NCT03193086	Glostrup University Hospital, Copenhagen\|Genzyme, a Sanofi Company	Multiple Sclerosis	January 1, 2017
NCT00771602	M.D. Anderson Cancer Center\|Genzyme, a Sanofi Company	Chronic Lymphocytic Leukemia\|Leukemia	August 2008	Phase 2
NCT01446484	Pirogov Russian National Research Medical University\|Russian Academy of Medical Sciences	End-Stage Renal Disease\|Kidney Failure	October 2011	Phase 1\|Phase 2
NCT04018937	Emory University	Sickle Cell Disease	March 22, 2019	Phase 2
NCT01120028	University of Oxford\|National Health Service, United Kingdom\|Pfizer\|Novartis	Kidney Transplantation	September 2010	Phase 2\|Phase 3
NCT00276809	German CLL Study Group	Chronic Lymphocytic Leukemia	June 2001	Phase 2
NCT00281983	German CLL Study Group	Chronic Lymphocytic Leukemia	June 2000	Phase 1\|Phase 2
NCT00004857	Alliance for Clinical Trials in Oncology\|National Cancer Institute (NCI)	Leukemia	January 2000	Phase 2
NCT00836043	Genzyme, a Sanofi Company\|Sanofi	Chronic Lymphocytic Leukemia	October 2008
NCT02162420	Masonic Cancer Center, University of Minnesota	Dyskeratosis Congenita\|Aplastic Anemia	January 2015	Not Applicable
NCT00533923	Beth Israel Deaconess Medical Center\|Bayer	AML\|ALL\|CLL\|Myelodysplastic Syndrome\|Non-Hodgkin´s Lymphoma\|Hodgkin´s Lymphoma\|Multiple Myeloma\|Aplastic Anemia\|Myeloproliferative Disorder	December 2002	Phase 2
NCT00436904	Mayo Clinic\|National Cancer Institute (NCI)	Leukemia	December 2004	Phase 2
NCT01182675	University of California, San Francisco	Severe Combined Immunodeficiency	August 2010	Phase 2
NCT00698685	University of Arizona\|National Cancer Institute (NCI)	Leukemia\|Lymphoma\|Hodgkin´s Disease\|Hematologic Neoplasms\|Multiple Myeloma\|Carcinoma, Renal Cell	January 23, 2006	Phase 2
NCT00582894	University of Oklahoma	Hematological Neoplasms\|Hematopoietic Stem Cell Transplantation	February 2005	Not Applicable
NCT03504241	National Institute of Allergy and Infectious Diseases (NIAID)\|Immune Tolerance Network (ITN)\|PPD\|Rho Federal Systems Division, Inc.	Kidney Transplantation\|Renal Transplantation\|Renal Transplant Recipient	July 30, 2018	Phase 1
NCT00001984	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)\|National Institutes of Health Clinical Center (CC)	Graft Rejection\|Kidney Disease	November 1999	Phase 2
NCT00051701	Genzyme, a Sanofi Company\|Sanofi	Non-Hodgkins Lymphoma	December 2002	Phase 1\|Phase 2

Appearance

Liquid

Shipping

Shipping with dry ice.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

References

[1] Kashani N, et al. Immune Regulatory Cell Bias Following Alemtuzumab Treatment in Relapsing-Remitting Multiple Sclerosis. Front Immunol. 2021;12:706278. Published 2021 Oct 28.